Farrow Financial’s Lineage Cell Therapeutics LCTX Stock Holding History

Farrow Financial’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$10.2K	Hold	10,646	–	–	0.01%	54
2026 Q2	$13.9K	Sell	10,646 -854	-7%	-$1.18K	0.01%	55
2026 Q1	$18.2K	Hold	11,500	–	–	0.01%	53
2025 Q4	$19.2K	Hold	11,500	–	–	0.01%	53
2025 Q3	$19.4K	Hold	11,500	–	–	0.01%	53
2025 Q2	$10.4K	Hold	11,500	–	–	0.01%	51
2025 Q1	$5.19K	Hold	11,500	–	–	﹤0.01%	50
2024 Q4	$5.7K	Hold	11,500	–	–	﹤0.01%	50
2024 Q3	$10.4K	Hold	11,500	–	–	0.01%	52
2024 Q2	$11.5K	Hold	11,500	–	–	0.01%	50
2024 Q1	$17K	Sell	11,500 -5,500	-32%	-$6.24K	0.01%	53
2023 Q4	$18.5K	Buy	+17,000	New	+$18.6K	0.01%	51

Other funds holding LCTX

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return

Hofer & Associates Thousand Oaks, California $143M AUM 11.29% 1-Year Est. Return

Red Crane Wealth Management San Francisco, California $143M AUM 13.63% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Williams Jones Wealth Management New York $8.94B AUM 17.99% 1-Year Est. Return

Farrow Financial's LCTX Position: Q3 2026 in Review

Farrow Financial held its Lineage Cell Therapeutics (LCTX) position steady in Q3 2026 at 10,646 shares worth $10.2K. The position accounts for 0.01% of the portfolio, ranked #54.

Farrow Financial first reported a position in LCTX in Q4 2023 and has held it in 12 quarters since. The position peaked at $19.4K in Q3 2025. 57 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

Farrow Financial held 10,646 shares of Lineage Cell Therapeutics worth $10.2K as of Q3 2026.
Farrow Financial left its Lineage Cell Therapeutics share count unchanged in Q3 2026.
Lineage Cell Therapeutics made up 0.01% of Farrow Financial's portfolio in Q3 2026, its #54 holding.
Farrow Financial first reported a position in Lineage Cell Therapeutics in Q4 2023 and has held it in 12 quarters since.
Farrow Financial's Lineage Cell Therapeutics position peaked at $19.4K in Q3 2025.
57 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Farrow Financial's 13F filing for Q3 2026, filed 30 Oct 2026.